AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
4.240
-0.230 (-5.15%)
At close: Aug 1, 2025, 4:00 PM
4.220
-0.020 (-0.47%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Company Description

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.

Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.

The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc.
AbCellera Biologics logo
CountryCanada
Founded2012
IPO DateDec 11, 2020
IndustryBiotechnology
SectorHealthcare
Employees596
CEOCarl Hansen

Contact Details

Address:
150 West 4th Ave
Vancouver, BC V5Y 1G6
Canada
Phone604 559 9005
Websiteabcellera.com

Stock Details

Ticker SymbolABCL
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$20.00
CIK Code0001703057
CUSIP Number00288U106
ISIN NumberCA00288U1066
SIC Code2834

Key Executives

NamePosition
Dr. Carl L.G. Hansen Ph.D.Chief Executive Officer, President and Chairperson
Andrew Booth M.B.A.Chief Financial Officer
Dr. Veronique Lecault Ph.D.Chief Technology Officer and Director
Tryn T. Stimart Esq., J.D., M.Sc.Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary and Privacy Officer
Marcie Thiessen CPA, CGASenior Director of Finance and Accounting
Tiffany Chiu B.Sc., Ph.D.Vice President of Communications
Graham Craig M.Sc.Director of Corporate Development
Murray McCutcheon Ph.D.Senior Vice President of Partnering
Neil Aubuchon B.A., M.B.A.Chief Commercial Officer
Adam Clarke M.A.I.C.D., Ph.D.Senior Vice President of Discovery

Latest SEC Filings

DateTypeTitle
Jun 13, 20258-KCurrent Report
May 30, 20258-KCurrent Report
May 14, 20258-KCurrent Report
May 13, 20258-KCurrent Report
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 29, 2025ARSFiling
Apr 29, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2025DEF 14AOther definitive proxy statements
Feb 27, 2025S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuers